Optimized QRT-PCR Approach for the Measurable Impact of Adjuvant Cholecalciferol Therapy in Ameliorating Cytokine Gene Expression


ABSTRACT

The endemic Vitamin D deficiency in Pakistan and the current COVID-19 epidemic have converged into a double whammy scenario in Pakistan [1]. Nutritional epigenomic studies have highlighted Vitamin D as a master Vitamin influencing various genomic expressions through its active metabolite 1α,25-dihydroxyvitamin D3 [2]. The objective of this study was to evaluate the measurable impact of adjuvant Cholecalciferol therapy in the Cytokine gene expression of COVID-19 patients by quantitative Real-Time Polymerase Chain Reaction analysis. The trial was a randomized control prospective open label interventional trial done on moderate to severe COVID-19 patients with deranged inflammatory and coagulation biomarkers, SunnyD STAT (Vitamin D3 200000 IU) softgels were given at Day 1, Day 3 and Day 5 of the treatment. Optimized quantitative Real-Time Polymerase Chain Reaction analysis showed decreased genetic expressions of Interleukin 6 (IL-6), Interleukin 2RA (IL-2RA) and Tumor Necrosis Factor (TNF-a) in the interventional group against the age and co-morbidities matched controls, providing molecular and genetic level evidence for the purported mechanism of amelioration of Cytokines induced pathogenic inflammation. However, inherent limitations of the design restrict the generalizability of the results and warrants caution for extrapolation. We recommend randomized placebo-controlled trials with larger sampling and genome wide profiling to infer more definite interpretations.

Keywords: Adjuvant therapy, Cholecalciferol, genetic expression, vitamin D3.

I. INTRODUCTION

Nutritional epigenomic studies have highlighted Vitamin D as a master Vitamin influencing various genomic expressions through its active metabolite 1α,25-dihydroxyvitamin D3 [2]. The activated Calcitriol binds to the nuclear Vitamin D Receptor (VDR), and confers its actions on thousands of loci within the human genome, consequently effecting the human epigenetics and transcriptome [2].

The pluripotential role of Vitamin D includes directly effecting the genetic expression of various inflammatory proteins, modulating the transcription factor activity and stimulating a cascade of intra cellular signaling [3]. Our study explores these interactions through genetic expressions as a possible molecular explanation for the early therapeutic intervention in the context of COVID-19.

II. BACKGROUND

The inert photosynthesized or dietary Vitamin D binds to the Gc globulin protein in the blood stream, the Vitamin D Binding Protein (DBP), and undergoes hepatic and renal hydroxylation for its conversion to its active metabolite 1,25(OH)2D [4]. Although the renal activation through CYP27B1 transcription is mainly dictated by the internal Calcium milieu of the body, an autocrine and paracrine fashion is followed through its high affinity attachment to the (kD 0.1 nM) ligand activated member of the transcription family of the nuclear receptors, the Vitamin D Receptor (VDR) in the extra renal tissues [5]. Consequently, heterodimerization of the VDR with Retinoid X Receptor (RXR) along with vitamin D response elements (VDREs) associated activation of the transcription factors is induced by this binding of 1,25(OH)2D with the VDRs [6]. The binding is specific to the response elements composed of 3 bp (DR3 elements) separating the direct repeats of 5′-PuGG/TTCAG-3′. Moreover, genetic repression with heterogeneous mechanisms is revealed though individual gene profiling.

DOI: http://dx.doi.org/10.24018/ejmed.2021.3.6.1117
studies requiring interactions with other classes of transcription factors also [8].

The activated Vitamin D Receptor binds to as many as nearly 20,000 loci within the chromatin, activating or repressing nearly 50% of the target genes it regulates, bringing about the genetic regulation of pluripotent physiological including the modulation of Cytokines gene expression in the immune system [9].

A. Molecular VDR Influenced Genomic Activity

The Vitamin D Receptor belongs to the Nuclear Receptors family, which are focused on various metabolic activities of the body [10]. Sensing the activated 1α,25-dihydroxyvitamin D3, these Vitamin D Receptors express the genes in various tissues and cells of the human body, influencing their differentiation and epigenetic programming [11]. For instance, the binding of pioneer transcription factor, CCCTC binding factor or CTCF binding can be influenced by Vitamin D through VDR mediated binding to the less dense euchromatin through its genomic binding sites [12]. Moreover, Vitamin D can also influence the formation of Topologically Associated Domains (TADs), histone modifications and regulation of gene expression by modifying accessibility to Chromatin [13]. The Vitamin D Receptor, including its other family of nuclear receptors like RAR, PPAR, LXR, forms a heterodimer with retinoid X receptor [14]. This is evident through established VD signaling models. This complex prefers to bind to DR3-type response elements of the DNA where a repeat of 2 hexameric motifs is spaced by 3 nucleotides [15]. Moreover, this preferential motifs’ binding of VDR to DR3-type sequences is confirmed through obtaining the VDR cistrome in a number of cell lines [16].

B. Direct Epi-genomic Translational Effects of Vitamin D

Interesting to highlight here is that the Vitamin D Receptor binds to only 200-2000 sites, depending on cell type, in the absence of a ligand [17]. However, the sites are increased by a factor of 2.5 after stimulation with the activated Calcitriol [18], marking the first direct epigenomic effect of Vitamin D [15]. The second effect is the modulation of nearly 10% of the binding sites of the cistrome subsets including the purine-rich box 1 (PU.1), CEBPA and GABPA [19]. Moreover, nearly 1300 sites of the transcription factor CCCTC genome (CTCF) are also influenced by its activated form [20]. Another effect of 1,25(OH)2D3, especially on THP-1 cells, is that it modulates the chromatin 3D structure through the Topologically Associated Domains (TADs) produced by the VDR sensitive CTCF [21]. Finally, 1,25(OH)2D3 changes the chromatin accessibility by modifying the histone complex through the ligand-dependent interference of VDR [22] (Fig 1).

C. Antagonization of Pro Inflammatory Transcription Factors by Vitamin D Receptor

The main genomic role of Vitamin D in chronic inflammatory and autoimmune conditions involves the major histocompatibility complex and its co-stimulatory molecules including CD40, CD80 and CD86, which are repressed through their genetic codes by Vitamin D [23], [24]. Antagonization of pro inflammatory transcription factors by Vitamin D Receptor and its ligands leads to decreased Cytokine expression of interleukins [25]. A study shortlisted 15 genes as the major targets of Vitamin D in the immune system, majority of which were found to encode proteins present in or on the cellular membranes, including SEMA6B, TREM1, LILRB4, NINJ1, CD14, THBD, CD93, LRRC25, ACVRL1 [26].

D. Impact on Cytokine Gene Expression of IL-6, IL-2 and TNF-α

Since pro-inflammatory Cytokines like Interleukins-6, Interleukins-2 and Tumor Necrosis Factor-alpha are associated with the pathogenic inflammation in COVID-19, a study done on COVID-19 patients at Mont Sinai health system, New York, predicted the COVID-19 severity and survival through identifying inflammatory cytokine signatures, serving as predictive bio markers of pathogenic inflammation and impending Cytokine storm [27]. These signatures helped in guiding targetable immune pathways. Studies exploring applicability of this guide could be important. Moreover, the practical application of the use of Cytokine signature expressions guide is also lacking, especially in the context of 1,25(OH)D. Therefore, the objective of this randomized control trial was to identify the genetic level impact of loading Cholecalciferol adjuvant therapy (200000 IU on day 1, 3 and 5) on the Cytokine inflammatory signatures, by following its molecular pathway.

III. MATERIALS AND METHODS

A. RNA Isolation and Real-Time PCR Analysis for IL-2, IL-6 and TNF-α

Sample was collected in anti-coagulant Ethylenediaminetetraacetic acid [EDTA] tubes 1.5 ml and 2 ml [Eppendorf]. Nano-drops [RNA later Thermo Fisher Scientific] confirmed total RNA integrity. Cytokines Genetic expressions were done using peripheral blood mononuclear cells [PBMCs] through the direct binding asymmetrical Cyanine SYBR Green dye and Superscript III Platinum One Step Quantitative Real Time – Polymerase Chain Reaction kit.

Assessment of the mRNA genes expression of IL-6, IL2 and TNF-α was done with appropriate primers and probes. RT-PCR primer/Probe Sets by Applied Biosystems were used for the inflammatory and coagulation markers. Superscript III Platinum One Step Quantitative Real Time – Polymerase Chain Reaction kit [Thermo fisher], QI Aamp
Viral RNA Mini Kit [Qiagen Inc USA] and Phusion U Green Multiplex Polymerase Chain Reaction Master Mix and RNA later [Thermo Scientific™] were in use. Polymerase Chain Reaction amplification conclusion was made following 3 cycles comprising of the first warm up cycle for 15 seconds at 95 °C, second denaturation cycle at 56 °C for 30 seconds and finally 30 seconds at 72 °C acquiring Target SYBR Green.

B. Study Design and Ethical Approvals

The study design was a prospective open labeled randomized interventional trial executed at Akram Medical Complex, Lahore and Jinnah hospital, Lahore in collaboration with University of Health Sciences, Lahore after receiving the ethical approvals by the Ethical Review Committee [ERC] of the University of Health Sciences, Lahore [rc no. UHS/REG-20/ERC/1762 dated 8 September 2020] and National Bioethical Committee [ref. no. 4-87/NBC-COVID-50/20/699 dated November 19,2020] and Clinical Trial Unit of the Drug Regulatory Authority of Pakistan [IN-1417/SN-2037470-1/CTU-DRAP dated November 26,2020]. Written informed consent was taken from all subjects.

C. Sampling

Classical markers like Ferritin, D-Dimers, CRP and LDH were used to stratify patients based on inflammation and disease severity for inclusion. Confirmed moderate to severe COVID-19 patients, age-matched 40-70 years with co-morbidities including Diabetes and cardiac disease, D-Dimers > 500 ng/ml, CRP > 10 mg/L, LDH = 125-243 U/L, Ferritin 20 to 500 ng/ml for males and 20 to 200 ng/ml for females were included while those with respiratory failure, shock, pregnancy, lactation or multiple organ damage were excluded. Openepi.com was used to calculate the sample size. Two-sided significance level (1-alpha) was taken as 95% and power of 80% with sample size ratio as 1. Sample size for control and interventional group, was calculated as 11 each (total 22). A total sample size of 26 was derived by Fl, with a power of 80% with sample size ratio as 1. Sample size for intervention and control group, was calculated as 11 each, with p=0.05 and Power 0.80. Openepi.com was used to calculate the sample size.

TABLE I: Baseline Characteristics of Participants N=50

<table>
<thead>
<tr>
<th>Gender n (%)</th>
<th>Male n (%)</th>
<th>Female n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZAge n (%)</td>
<td>Median</td>
<td>Mode</td>
</tr>
<tr>
<td>Co-morbidities n (%)</td>
<td>Diabetes</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Lab markers (Mean + SD)</td>
<td>D-Dimers (ng/ml)</td>
<td>LDH (U/L)</td>
</tr>
</tbody>
</table>

IV. RESULTS

Fold change in the gene expression of the molecular inflammatory markers including IL-6, IL-2RA and TNF-α was calculated. Down regulation of > 4-fold, > 2.5-fold and > 2-fold was observed in the molecular gene expression of Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-19.
Interleukin Receptor Alpha IL-2RA, respectively (Fig. 2, 3, 4).

A p-value of <0.05 was considered to be statistically significant. With this, the comparative analysis through paired t-test showed statistically significant (p<0.0001) reduction in the Cytokine genetic expression level as calculated for the interventional group, while the results were not so significant (p>0.05) for the age and comorbidities-matched controls using the quantification Cycle (Cq) indicating the amplification curve with respect to the cycle axis. The difference in expression of Cytokines between the groups (interventional versus control) was significant at p<0.05, with the expression being markedly high in the control group as compared to the interventional group (Table II).

One-way variance analysis (ANOVA) for each genetic expression variable was carried out. For Interleukin-6 (IL-6), a mean of 33.7571±0.7413 was calculated for the Cases, while the controls showed a mean of 31.705±1.1276 and the f-ratio value of 61.728. The p-value was statistically significant at <0.0001. For Interleukin Receptor Alpha (IL-2RA), the mean value was 33.9156±0.5144, while for the controls it was 32.3336±0.2690 the f-ratio value was calculated to be 185.68975. and the p-value was significant at <0.00001. For Tumor Necrosis Factor (TNF-α), the mean was 20.6444±0.5009 for the cases and 19.6776±0.4754 for the controls with the f-ratio value of 49.0012. The p-value was significant as it was <0.00001 (Table III).

### Table II: Comparative Analysis Through Paired T-Test

<table>
<thead>
<tr>
<th>Group</th>
<th>Cases (n=25)</th>
<th>Controls (n=25)</th>
<th>Two-tailed p value</th>
<th>95% CI</th>
<th>t</th>
<th>Df</th>
<th>SE of diff</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>20.6444±0.5009</td>
<td>19.6776±0.4754</td>
<td>&lt;0.0001</td>
<td>0.6406-1.2930</td>
<td>6.116</td>
<td>24</td>
<td>0.158</td>
</tr>
<tr>
<td>IL-6</td>
<td>33.7660±0.7545</td>
<td>31.6428±0.2294</td>
<td>&lt;0.0001</td>
<td>1.4926-2.7538</td>
<td>6.949</td>
<td>24</td>
<td>0.306</td>
</tr>
<tr>
<td>IL-2RA</td>
<td>33.946±0.5039</td>
<td>32.3336±0.2690</td>
<td>&lt;0.0001</td>
<td>1.4026-1.8230</td>
<td>15.84</td>
<td>24</td>
<td>0.102</td>
</tr>
</tbody>
</table>

### Table III: ANOVA One Way Test

<table>
<thead>
<tr>
<th>Cases</th>
<th>Control</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>33.7571±0.7413</td>
<td>31.705±1.1276</td>
</tr>
<tr>
<td>ΣX</td>
<td>945.2</td>
<td>760.92</td>
</tr>
<tr>
<td>ΣX²</td>
<td>31922.0888</td>
<td>24154.21</td>
</tr>
</tbody>
</table>

Results

<table>
<thead>
<tr>
<th>Source</th>
<th>SS</th>
<th>df</th>
<th>MS</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between groups</td>
<td>54.4228</td>
<td>1</td>
<td>54.4228</td>
<td>61.728</td>
</tr>
</tbody>
</table>

DOI: http://dx.doi.org/10.24018/ejmed.2021.3.6.1117
The rationale for using the selected inflammatory bio markers panel was based on existing literature. Studies have labelled Interleukins-6 as one of the most important and independent bio markers for COVID-19 prognosis with respect to mortality, survival, use of ventilation and end organ damage even more than the prognostic prediction offered by C-Reactive proteins and D-dimer levels, after adjustment with other potentially influencing factors like socio-demographic features and presence/absence of co-morbidities [28]-[33], [40]. Also, TNF-α has been highlighted as a strong predictor with increased levels associated with end organ damage and poor outcome after adjustment [34], [35], [40]. We also included Interleukin-2RA in our assessment panel of Cytokines because it has also been showing an independent association with survival time, after adjusting with all other co variables, in various studies [36]-[40]. Since pro inflammatory Cytokines like interleukins-6, interleukins-2 and Tumor Necrosis Factor-alpha are associated with the pathogenic inflammation in COVID-19, a study done on COVID-19 patients at Mont Sinai health system, New York, predicted the COVID-19 severity and survival through identifying inflammatory cytokine signatures, serving as predictive bio markers of pathogenic inflammation and impending Cytokine storm [40].

These signatures helped in guiding targetable immune pathways. Studies exploring applicability of this guide could be important. Therefore, we aimed to explore the molecular level impact of Vitamin D supplementation on the genetic expression of these pro inflammatory markers and to see the association if any with the serum 25(OH)D level.

Moreover, the practical application of the use of Cytokine signature expressions guide is also lacking. Therefore, the greater objective of this trial was to halt the impending danger of a Cytokine storm through identifying Cytokine inflammatory signatures at the genetic level and adding SunnyD STAT softgel (Vitamin D3 200000 IU) as an adjuvant therapy on day 1,3 and 5 of patient enrollment. Notably, the cytokine response of the interventional group showed statistically significant difference from the traditional treatment control group, which sustained elevated cytokine levels over the study period. This raises the possibility of a mitigation strategy with immune modulatory role of Vitamin D and the window of opportunity for its adjunctive use. This study might add to the guides for such adjunctive therapies based on mechanistic association and modulation of genetic

V. DISCUSSION

Although the two groups under randomization (controls and interventional) were matched with respect to their co-morbidities, age, vital parameters, symptoms intensity and duration, significant difference in the interventional and control groups after the intervention were intriguing.

Rapid increase in the serum Vitamin D3 levels after oral ingestion of softgel within a short period of time showed that the pharmacodynamics of softgel delivery system in raising serum 25(OH)D3 are favorable, when results are required urgently. The rapid and significant decrease in the coagulation and bio inflammatory markers after the adjuvant therapy of Vitamin D, point toward the immunomodulatory potential of Vitamin D in COVID-19 and early identification and treatment can help in halting the impending Cytokine storm – the main perpetrator in COVID-19 related morbidities and mortalities.

To the best of our knowledge, this study is the first randomized control trial to evaluate the applicability of the predictive guide of the Cytokine genes signature expression, through adjunctive therapy of an immunomodulator in the form of Vitamin D3.

Thus, our results show promising role of loading doses of Vitamin D3 in the initial phases of COVID-19, modulated through the repercussions of a controlled immune response, to prevent the blistering pace entry into the immunological apocalpyse.

### Data Summary

<table>
<thead>
<tr>
<th>Source</th>
<th>SS</th>
<th>df</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between groups</td>
<td>31.2841</td>
<td>1</td>
<td>31.2841</td>
</tr>
<tr>
<td>Within group</td>
<td>8.0686</td>
<td>48</td>
<td>0.1685</td>
</tr>
<tr>
<td>Total</td>
<td>39.3708</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>

The f-ratio value is 185.68975. The p-value is <0.00001. The result is significant at p<0.05

### TNF-α Data Summary

<table>
<thead>
<tr>
<th>Source</th>
<th>SS</th>
<th>df</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between groups</td>
<td>11.6838</td>
<td>1</td>
<td>11.6838</td>
</tr>
<tr>
<td>Within group</td>
<td>11.4451</td>
<td>48</td>
<td>0.2384</td>
</tr>
<tr>
<td>Total</td>
<td>23.1289</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>

The f-ratio value is 49.0012. The p-value is <0.00001. The result is significant at p<0.05

### IL-2RA Data Summary

<table>
<thead>
<tr>
<th>Source</th>
<th>SS</th>
<th>df</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Between groups</td>
<td>29.1028</td>
<td>1</td>
<td>29.1028</td>
</tr>
<tr>
<td>Within group</td>
<td>18.7462</td>
<td>48</td>
<td>0.3855</td>
</tr>
<tr>
<td>Total</td>
<td>47.849</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>

The f-ratio value is 61.728. The p-value is <0.00001. The result is significant at p<0.05
expression of cytokines, providing a rational approach for future strategies.

VI. STRENGTHS AND LIMITATIONS

Due to the strict criteria for inclusion, age matching and molecular level real time multiplex analysis through RT-PCR, sample size could not be very large. Therefore, generalizability of the results should be extrapolated with caution. Additionally, the inherent limitations of an open labelled trial could be present. Future randomized placebo control large trials are warranted to infer more definite interpretations. However, to the best of our knowledge, this was the first randomized control trial, especially in this region, evaluating the adjuvant immune modulatory role of Vitamin D supplementation in the moderate-severe COVID-19 patients’ cohort, providing molecular and genetic level evidence for the purported mechanism of amelioration of Cytokines induced pathogenic inflammation.

VII. CONCLUSION

Genetic expression profiling of the Cytokines showed improvements after the addition of Cholecalciferol adjuvant therapy to the COVID-19 treatment regime, providing molecular and genetic level evidence for the purported mechanism of amelioration of Cytokines induced pathogenic inflammation. However, inherent limitations of the design restrict the generalizability of the results and warrants caution for extrapolation. We recommend randomized placebo-controlled trials with larger sampling and genome wide profiling to infer more definite interpretations.

ACKNOWLEDGEMENTS

We acknowledge Dr. Shehla Akram for providing and arranging patients at her Akram Medical Complex, Lahore and all those who were involved in the logistics and data collection process.

NOMENCLATURE

The general nomenclature used for this trial during inception, designing and execution was the VICCTORI trial denoting “Vitamin D In Corona Cytokine Therapy on Registered Inpatients”.

REFERENCES


Kalai V, Xiao H, Yuzefpolskiy Y, Sarkar S. IL-2 Signals Program the Fate of Exhausted CD8 T cells, 2019.